Education for your patients.

Meet Team Novo8™.

Different backgrounds. Different Stories. One mission.

They come from all walks of life. Their mission is the same: to share their inspirational stories of living with hemophilia A and what Novo Nordisk's commitment to the hemophilia community has meant to them. Click on each team member to learn about his or her story.

  • Meet Daniel

    Daniel DeRatto was diagnosed with severe hemophilia A at 5 months. As a boy, he learned that having hemophilia didn't have to be awkward; that most people would treat him the same as anyone else. To further encourage Daniel to take control of his condition, his mother, Patricia, actively supported his desire to play sports. Daniel understands the challenges of transitioning into adulthood while living with hemophilia. His mission is to speak to young children and teenagers about how to deal with the challenges of growing up with hemophilia.

  • Meet Vaughn

    Vaughn Ripley was diagnosed with mild hemophilia A at 18 months old. Growing up, his energetic and curious personality was a challenge because hemophilia limited his activities and left him feeling like he was “bubble-wrapped”.  Hemophilia treatment was different when Vaughn was young and his treatments often took 8 hours a day at the hospital. As a teenager, he contracted HIV from contaminated products and was told he had less than 2 years to live.  Although initially shaken by this news, Vaughn is not one to quit and now has his conditions under control.  As an adult, Vaughn is passionate about staying fit through diet and exercise as well as sharing his story with the world.  He also values a treatment that he can take with him as he lives the life he’s always craved.

  • Meet Brian

    Brian Almquist was diagnosed with hemophilia A at an early age. Because of the great support from the staff at his hemophilia treatment center, he learned how to be cautious while remaining very active. Throughout his life, Brian hasn't allowed hemophilia to limit his love of outdoor activities. Attending conferences, camps, and other hemophilia community events has also expanded his network of support and friendship. Brian's mission is to speak with families about his experiences living with hemophilia to remind them that they are not alone.

Meet Eric

Eric George was diagnosed with hemophilia A when he was born. Growing up in a family with 4 siblings who all have hemophilia taught him that the condition doesn't have to be a negative experience or stop you from achieving goals. In fact, he built a strong network around himself in the hemophilia community and he believes in the power of sharing experiences. His mission is to help others with bleeding disorders learn how to push past their challenges.

Selected Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Indications and Usage

Novoeight® (Antihemophilic Factor [Recombinant]) is indicated for use in adults and children with hemophilia A for control and prevention of bleeding, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

Novoeight® is not indicated for the treatment of von Willebrand disease.

Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Development of activity-neutralizing antibodies (inhibitors) may occur.  If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures factor VIII inhibitor concentration.

The most frequently reported adverse reactions (≥0.5%) were injection site reactions, increased hepatic enzymes, and pyrexia.

Please click here for Prescribing Information.